RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Daviddal, In the Roth presentation, Dr. Stoll said they were initiating another type of AD study (an "MEG" study, see slide 25), in addition to trying to complete the PET study. I'm not familiar with what MEG is however.

What I think is most likely to happen is that Cortex won't do any deals until after getting the word from the FDA on dosing liberalization (approx Q2/May). Then Cortex and BPs will know where we stand with CX-717, and will proceed from there. In the meantime (by early '07), Cortex will have to bite the bullet and do an unfavorable PIPE.